0.710
0.00 (0.00%)
| Previous Close | 0.710 |
| Open | 0.710 |
| Avg. Volume (3M) | 854 |
| Market Cap | 6,957,672 |
| Price / Sales | 2.89 |
| Price / Book | 1.26 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,196.25% |
| Diluted EPS (TTM) | -24.46 |
| Quarterly Revenue Growth (YOY) | 215.50% |
| Current Ratio (MRQ) | 0.070 |
| Operating Cash Flow (TTM) | -15.48 M |
| Levered Free Cash Flow (TTM) | 7.57 M |
| Return on Assets (TTM) | -68.49% |
| Return on Equity (TTM) | -727.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Orgenesis, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company’s business includes two reporting segments: Octomera and Therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 20.14% |
| % Held by Institutions | 0.79% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |